Munish Forge Ltd opened its Initial Public Offering (IPO) on September 30, 2025. The bidding window for the Munish Forge IPO was open till October 3, 2025, and the allotment process for the IPO is expected to be finalised today, on October 6, 2025. The shares of Munish Forge Limited will be listed on NSE, and the tentative listing date is fixed as October 8, 2025.
Here is the process to check Sheel Biotech IPO Allotment on NSE:
[October 3, 2025, end of the day]
On day 3, Munish Forge's IPO was subscribed 3.53 times. The public issue was subscribed to 2.66 times in the individual investors category, 4.05 times in QIB, and 4.88 times in the NII category.
Munish Forge IPO was a book build issue of ₹73.92 crores. The issue comprises a fresh issue of 0.64 crore shares, aggregating to ₹61.02 crores, and an offer for sale of 0.13 crore shares, aggregating to ₹12.90 crores. The IPO price band was set at ₹91 to ₹96 per share. The minimum lot size for an application was 1200. The minimum amount of investment required by an individual investor (retail) was ₹2,30,400.00 (2,400 shares) based on the upper price.
Gretex Corporate Services Ltd. was the book running lead manager, and Skyline Financial Services Pvt.Ltd was the registrar of the issue. The Market Makers of the company were Gretex Share Broking Pvt.Ltd and NNM Securities Pvt.Ltd.
Munish Forge Limited, established in 1986 and headquartered in Ludhiana, Punjab, is a leading manufacturer of precision-forged and cast components. The company specialises in producing tank track chains, bomb shells, flanges, scaffolding, auto parts, and fence posts, serving sectors such as defence, oil & gas, automotive, infrastructure, and construction.
For the fiscal year ending March 31, 2024, Munish Forge reported operating revenues between ₹100 crore and ₹500 crore. The company has demonstrated a 29.94% increase in EBITDA and a 13.34% growth in net worth compared to the previous year.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.